SAN DIEGO--(EON: Enhanced Online News)--bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, today announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerTYPE ID® molecular cancer classification test, as part of its surgical pathology consultants, to aid in the management of patients with metastatic cancer.
As part of the agreement, the CancerTYPE ID test will be available to Mayo Clinic physicians and patients, as well as to more than 5,000 hospitals around the world served by Mayo Medical Laboratories.
CancerTYPE ID, an industry-leading molecular cancer classifier, predicts tumor type in patients with metastatic cancers, which affect more than 400,000 patients in the United States each year and are among the most difficult to diagnose and treat. The CancerTYPE ID test is supported by clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification, and impact on patient outcomes.
Richard Ding, president and CEO of bioTheranostics, said, “We are pleased that Mayo Clinic will offer the CancerTYPE ID test to patients and physicians as a proven tool in the management of metastatic cancer. This expands the availability of this advanced diagnostic test and supports our commitment to personalized medicine for metastatic cancer patients—the first step of which is to obtain an accurate diagnosis.”
About Mayo Clinic
About Mayo Medical Laboratories
Mayo Clinic offers proven diagnostic tests to more than 5,000 healthcare institutions around the world through Mayo Medical Laboratories, Mayo Clinic’s reference laboratory. Revenue from Mayo Medical Laboratories’ testing is used to support medical education and research at Mayo Clinic. Learn more at www.MayoMedicalLaboratories.com.
bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung, colorectal, and other cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.